Conditions: Atherosclerosis
Keywords: SB-480848 Dyslipidaemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 107
Healthy volunteers: no

Brief summary:
The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.

Detailed description:

Arms:
arm 1: Matched Placebo arm 2: SB480848 40mg/day arm 3: SB480848 80mg/day arm 4: SB480848 160mg/day

Interventions: intervention 1: SB480848 40mg EC Tablet intervention 2: SB480848 80mg EC Tablet intervention 3: SB480848 160mg EC Tablet intervention 4: SB480848 Placebo Tablet
Intervention descriptions: intervention 1: 1 tablet once a day intervention 2: 1 tablet once a day intervention 3: 1 tablet once a day intervention 4: 1 tablet once a day

Protocol document: